aSurgical Health Outcomes & Research Enterprise (SHORE), University of Rochester Medical Center, Rochester, NY
bDepartment of Medicine, Hematology/Oncology Division, University of Rochester Medical Center, Rochester, NY
cDepartment of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic Florida, Weston, FL
dDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
eDepartment of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH
Correspondence address: Fergal J Fleming, MD, Surgical Health Outcomes & Research Enterprise (SHORE), Department of Surgery, University of Rochester Medical Center, 601 Elmwood Ave, Box SURG, Rochester, NY 14642.
E-mail: [email protected]
Submitted February 18, 2015; revised April 6, 2015; accepted April 9, 2015.
Disclosure Information: Nothing to disclose.
Disclosures outside the scope of this work: Dr Wexner is a consultant for CareFusion, Edwards LifeSciences, GI View, Incontinence Devices Inc, Johnson & Johnson Medical, Karl Storz Endoscopy-America, Lexington Medical, LifeBond, Mederi Therapeutics, Medtronic, Novadaq, Precision Therapeutics, and Renew Medical. Dr Wexner holds patents and receives royalties from Covidien, Karl Storz Endoscopy-America, novoGI, and Unique Surgical Innovations. Dr Wexner has stock and stock options for Asana Medical, LifeBond, CRH Medical, EZ Surgical, Neatstitch, and novoGI. All other authors have nothing to disclose.